更年期潮熱治療市場－全球產業規模、佔有率、趨勢、機會和預測，按類型、治療類型、配銷通路、地區和競爭細分，2020-2030 年

2024年，全球更年期潮熱治療市場規模達64.5億美元，預計2030年將達87.9億美元，預測期內複合年成長率為5.43%。全球更年期潮熱治療市場正在快速發展，這得益於人們對女性健康問題的認知不斷提高，以及對更年期有效症狀管理的需求不斷成長。隨著越來越多的女性尋求緩解潮熱帶來的不適和困擾，市場上湧現出各種各樣的治療方案。這些方案包括荷爾蒙替代療法、非荷爾蒙藥物、草藥以及以生活方式為導向的解決方案，例如膳食補充劑和健康計劃。

市場概覽
預測期	2026-2030
2024年市場規模	64.5億美元
2030年市場規模	87.9億美元
2025-2030 年複合年成長率	5.43%
成長最快的領域	醫院藥房
最大的市場	北美洲

製藥公司不斷投入研發，以研發出既有效又副作用更少的療法。例如，《更年期學會雜誌》2023年12月的一篇文章報導了一項線上研究的結果，該研究涉及巴西、加拿大、墨西哥和幾個北歐國家等國家的12,268名停經後女性。研究顯示，約15.6%的女性經歷了中度至重度血管舒縮症狀(VMS)。這種普遍的患病率預計將在未來幾年推動市場成長。荷爾蒙療法因其已被證實的療效而仍然被廣泛使用，但對長期安全性的擔憂導致人們對非荷爾蒙替代療法的興趣日益濃厚。這些替代療法對無法或不願接受荷爾蒙療法的女性尤其有吸引力，推動了選擇性血清素再攝取抑制劑、植物療法和穿戴式冷卻技術的創新。除了傳統的治療途徑外，個人化照護和整體健康方法也呈現出顯著的轉變。醫療保健提供者擴大採用綜合治療方案，不僅考慮更年期的身體症狀，還考慮情緒和心理方面的影響。遠距醫療平台和數位健康工具在患者參與方面也發揮著越來越重要的作用，從而實現更好的管理和後續護理。

人口結構和社會變化也在塑造著市場，例如女性老化人口的成長以及許多地區對更年期污名化的消除。這種文化轉變賦予了更多女性尋求專業醫療協助和高品質治療的權利。因此，市場預計將持續成長，為老牌企業和新進業者帶來機遇，它們將提供創新療法，以滿足全球更年期女性多樣化且不斷變化的需求。

關鍵市場促進因素

人們對更年期相關健康問題的認知不斷提高

主要市場挑戰

荷爾蒙療法的安全問題

主要市場趨勢

非荷爾蒙療法日益受到青睞

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球更年期潮熱治療市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按類型（口服液 vs 藥丸）
  • 依治療類型（荷爾蒙治療、非荷爾蒙治療、替代治療）
  • 荷爾蒙治療（雌激素、雌激素-黃體素組合、黃體素）
  • 非荷爾蒙治療（可樂定、加巴噴丁、普瑞巴林、Brisdelle、抗憂鬱藥物）
  • 替代療法（維生素 E、草藥、黑升麻）
  • 按配銷通路（醫院藥房、零售藥房和網路藥房）
  • 按地區
  • CompaBy 出品 (2024)
• 產品地圖

第6章：北美更年期潮熱治療市場展望

• 市場規模和預測
• 市場佔有率和預測
  • 荷爾蒙治療
  • 非荷爾蒙治療
  • 替代治療
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲更年期潮熱治療市場展望

• 市場規模和預測
• 市場佔有率和預測
  • 荷爾蒙治療
  • 非荷爾蒙治療
  • 替代治療
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區更年期潮熱治療市場展望

• 市場規模和預測
• 市場佔有率和預測
  • 荷爾蒙治療
  • 非荷爾蒙治療
  • 替代治療
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：南美洲更年期潮熱治療市場展望

• 市場規模和預測
• 市場佔有率和預測
  • 荷爾蒙治療
  • 非荷爾蒙治療
  • 替代治療
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東與非洲更年期潮熱治療市場展望

• 市場規模和預測
• 市場佔有率和預測
  • 荷爾蒙治療
  • 非荷爾蒙治療
  • 替代治療
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 近期發展
• 併購
• 產品發布

第 13 章：全球更年期潮熱治療市場：SWOT 分析

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章：競爭格局

第 15 章：1 Abbvie, Inc.

第 15 章：2 艾爾建公司。

第 15 章：3 拜耳股份公司。

第 15 章：4 Cipla, Inc.

第 15 章：5 禮來公司。

第 15 章：6 Emcure Pharmaceuticals Ltd.

第 15 章：7 葛蘭素史克公司。

第 15 章：8 Glenmark 製藥股份有限公司

第 15 章：9 久光藥株式會社

第 15 章：10 默克公司

第 16 章：策略建議

第17章調查會社について,免責事項

Global Menopausal Hot Flashes Treatment Market was valued at USD 6.45 billion in 2024 and is expected to reach USD 8.79 billion by 2030 with a CAGR of 5.43% during the forecast period. The global menopausal hot flashes treatment market is evolving rapidly, driven by growing awareness of women's health issues and increasing demand for effective symptom management during menopause. As more women seek relief from the discomfort and disruption caused by hot flashes, the market is witnessing the introduction of a diverse range of treatment options. These include hormone replacement therapies, non-hormonal pharmaceuticals, herbal remedies, and lifestyle-oriented solutions such as dietary supplements and wellness programs.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 6.45 Billion
Market Size 2030	USD 8.79 Billion
CAGR 2025-2030	5.43%
Fastest Growing Segment	Hospital Pharmacies
Largest Market	North America

Pharmaceutical companies are continuously investing in research and development to formulate therapies that are both effective and carry fewer side effects. For example, a December 2023 article in the Journal of the Menopause Society reported findings from an online study involving 12,268 postmenopausal women across countries like Brazil, Canada, Mexico, and several Nordic nations. It revealed that around 15.6% experienced moderate to severe vasomotor symptoms (VMS). This widespread prevalence is anticipated to fuel market growth in the coming years. Hormone-based treatments remain widely used due to their proven efficacy, but concerns around long-term safety have led to a rising interest in non-hormonal alternatives. These alternatives are particularly appealing to women who are unable or unwilling to undergo hormone therapy, fueling innovation in selective serotonin reuptake inhibitors, plant-based treatments, and wearable cooling technologies. In addition to traditional treatment avenues, there is a notable shift toward personalized care and holistic wellness approaches. Healthcare providers are increasingly adopting integrated treatment plans that consider not only physical symptoms but also the emotional and psychological aspects of menopause. Telemedicine platforms and digital health tools are also playing a growing role in patient engagement, enabling better management and follow-up care.

The market is also being shaped by demographic and social changes, such as the growing population of aging women and the destigmatization of menopause in many regions. This cultural shift is empowering more women to seek professional medical help and demand high-quality treatments. As a result, the market is poised for continued growth, with opportunities emerging for both established players and new entrants offering innovative therapies that cater to the diverse and changing needs of menopausal women across the globe.

Key Market Drivers

Rising Awareness of Menopause-Related Health Issues

Rising awareness of menopause-related health issues has become a pivotal force driving the global menopausal hot flashes treatment market. For many years, menopause was considered a private or even taboo topic, leading to limited discussion and a lack of proactive medical engagement. However, in recent years, societal attitudes have shifted significantly. Health organizations, advocacy groups, and media platforms are increasingly highlighting the challenges women face during menopause, especially the disruptive symptoms such as hot flashes, night sweats, and sleep disturbances. This growing visibility has empowered women to seek medical advice and explore available treatment options more confidently. For example, in May 2023, the U.S. Food and Drug Administration approved Veozah (fezolinetant), an oral treatment for moderate to severe vasomotor symptoms, commonly known as hot flashes, associated with menopause. The introduction of such innovative therapies is likely to enhance access to menopausal treatments and support market growth in the coming years.

Educational initiatives and awareness campaigns are playing a critical role in informing women about the physiological changes associated with menopause and the importance of timely intervention. These efforts are not only helping women recognize symptoms earlier but also encouraging open dialogue with healthcare providers. As a result, there is a notable increase in consultations related to menopause management, leading to greater demand for both pharmaceutical and non-pharmaceutical solutions.

Healthcare professionals are also becoming more proactive in addressing menopausal symptoms during routine check-ups, further normalizing the conversation around menopause. At the same time, the digital era has enabled access to a vast pool of information, forums, and telemedicine services, making it easier for women to educate themselves and connect with specialists from the comfort of their homes.

The increased focus on women's health across global health agendas is also pushing policymakers and healthcare providers to prioritize menopause management. This has led to the development of specialized clinics, wellness programs, and tailored treatment regimens, all aimed at improving quality of life during this transition. In turn, this heightened awareness is translating into a larger, more engaged consumer base actively seeking effective solutions for hot flashes, thereby propelling the growth of the menopausal hot flashes treatment market.

Key Market Challenges

Safety Concerns Around Hormone Therapy

Safety concerns around hormone therapy remain one of the most significant challenges in the global menopausal hot flashes treatment market. While Hormone Replacement Therapy (HRT) has long been considered the most effective option for alleviating hot flashes and other vasomotor symptoms associated with menopause, its potential risks have created a climate of caution among both patients and healthcare providers. Studies linking long-term hormone use-particularly estrogen-progestin combinations-to increased risks of breast cancer, blood clots, stroke, and cardiovascular events have led to heightened scrutiny of HRT prescriptions.

These safety concerns have prompted regulatory authorities to issue strict guidelines on the use of hormone therapy, recommending the lowest effective dose for the shortest possible duration. As a result, many women and clinicians are either reluctant to initiate or continue HRT, particularly in cases where the patient has a personal or family history of hormone-sensitive conditions. This has limited the therapy's appeal, despite its proven efficacy, and has created a significant demand for safer, non-hormonal alternatives. Moreover, the fear surrounding hormone therapy has contributed to misinformation and confusion, causing some women to avoid treatment altogether even when they might benefit from it. This underscores the need for clearer patient education and better risk-benefit communication by healthcare professionals.

These ongoing safety concerns are reshaping the treatment landscape, pushing pharmaceutical companies to innovate and develop non-hormonal therapies with better safety profiles. Addressing these concerns effectively is crucial for expanding patient access and building trust in the evolving options available for managing menopausal hot flashes.

Key Market Trends

Growing Preference for Non-Hormonal Therapies

The growing preference for non-hormonal therapies is emerging as a defining trend in the global menopausal hot flashes treatment market. Historically, hormone replacement therapy (HRT) has been the most widely used and effective option for managing vasomotor symptoms like hot flashes. However, concerns surrounding the long-term safety of HRT-including increased risks of breast cancer, stroke, and cardiovascular conditions-have led many women to seek alternative treatments. This shift in preference has opened the door for the development and adoption of non-hormonal therapies that offer relief without the potential complications associated with hormones.

Non-hormonal treatments encompass a wide range of options, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), gabapentin, and clonidine. These medications, often prescribed off-label, have shown effectiveness in reducing hot flashes and night sweats. More recently, advancements in drug development have introduced targeted non-hormonal therapies such as neurokinin-3 (NK3) receptor antagonists, which directly act on brain pathways that regulate temperature, offering a novel mechanism of action for symptom relief. In addition to pharmaceuticals, there is increasing consumer interest in herbal supplements and plant-based remedies, such as black cohosh, soy isoflavones, and red clover. These options appeal to women looking for natural or integrative approaches, further broadening the spectrum of non-hormonal interventions. This trend is particularly important for women who are not eligible for HRT due to medical contraindications or personal choice. As healthcare providers become more aware of and confident in these alternatives, and as patients demand safer and more personalized options, the market for non-hormonal therapies is expected to expand significantly. The growing preference for such treatments underscores a broader movement toward risk-averse, patient-centric care and is reshaping the direction of innovation in the menopausal hot flashes treatment landscape.

Key Market Players

• Abbvie, Inc.
• Allergan PLC.
• Bayer Ag.
• Cipla, Inc.
• Eli Lilly and Company.
• Emcure Pharmaceuticals Ltd.
• GSK PLC.
• Glenmark Pharmaceuticals Ltd.
• Hisamitsu Pharmaceutical Co. Inc.
• Merck & Co. Inc.

Report Scope:

In this report, the Global Menopausal Hot Flashes Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Menopausal Hot Flashes Treatment Market, By Type:

• Oral
• Liquid
• Pill

Menopausal Hot Flashes Treatment Market, By Treatment Type:

• Hormonal Treatment
• Non-Hormonal Treatment
• Alternative Treatment

Menopausal Hot Flashes Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Menopausal Hot Flashes Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Menopausal Hot Flashes Treatment Market.

Available Customizations:

Global Menopausal Hot Flashes Treatment Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Menopausal Hot Flashes Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Oral Liquid v/s Pill)
  • 5.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
  • 5.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
  • 5.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
  • 5.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By CompaBy (2024)
• 5.3. Product Map

6. North America Menopausal Hot Flashes Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (Oral Liquid v/s Pill)
  • 6.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
  • 6.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
  • 6.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
  • 6.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
  • 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Menopausal Hot Flashes Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Menopausal Hot Flashes Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Menopausal Hot Flashes Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By Distribution Channel

7. Europe Menopausal Hot Flashes Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (Oral Liquid v/s Pill)
  • 7.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
  • 7.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
  • 7.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
  • 7.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
  • 7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Menopausal Hot Flashes Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. GermaBy Menopausal Hot Flashes Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Menopausal Hot Flashes Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Menopausal Hot Flashes Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment Type
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Menopausal Hot Flashes Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment Type
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Menopausal Hot Flashes Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type (Oral Liquid v/s Pill)
  • 8.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
  • 8.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
  • 8.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
  • 8.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
  • 8.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Menopausal Hot Flashes Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Menopausal Hot Flashes Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Menopausal Hot Flashes Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Menopausal Hot Flashes Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment Type
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Menopausal Hot Flashes Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment Type
      • 8.3.5.2.3. By Distribution Channel

9. South America Menopausal Hot Flashes Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type (Oral Liquid v/s Pill)
  • 9.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
  • 9.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
  • 9.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
  • 9.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
  • 9.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Menopausal Hot Flashes Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Menopausal Hot Flashes Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Menopausal Hot Flashes Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Menopausal Hot Flashes Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type (Oral Liquid v/s Pill)
  • 10.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
  • 10.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
  • 10.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
  • 10.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
  • 10.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Menopausal Hot Flashes Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment Type
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Menopausal Hot Flashes Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment Type
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Menopausal Hot Flashes Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment Type
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Menopausal Hot Flashes Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

15.1 Abbvie, Inc.

15.2 Allergan PLC.

15.3 Bayer Ag.

15.4 Cipla, Inc.

15.5 Eli Lilly and CompaBy.

15.6 Emcure Pharmaceuticals Ltd.

15.7 GSK PLC.

15.8 Glenmark Pharmaceuticals Ltd.

15.9 Hisamitsu Pharmaceutical Co. Inc.

15.10 Merck & Co. Inc.

16. Strategic Recommendations

17. About Us & Disclaimer